The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled pre-and post-treatment design. Thirty patients with chronic epilepsy were administered a battery of cognitive tests and QoL measures at baseline (pre-treatment) and again following l-2 months of treatment (post-treatment). All patients were receiving anticonvulsant medication at baseline. Following baseline assessment, 15 patients were started on gabapentin as add-on therapy (gabapentin group), and 15 patients remained on stable medication (control group). No between-group treatment effects were demonstrated on any of the mood measures. A significant between-group treatment effect was demonstrated on one cognitive measure, in favour of the gabapentin group. Results do not suggest any adverse short-term effects of gabapentin on cognition or QoL in patients with chronic epilepsy.
INTRODUCTION
The influence of anticonvulsant drugs on cognitive function has been an important area of research interest in recent years. Most studies have been carried out on the standard treatments, notably phenobarbitone, phenytoin, and carbamazepine. While there has been some debate as to the differences between these'v2, there seems to be agreement that all of this generation of drugs affects cognition in some way. The search for treatments with minimal adverse effects was important in stimulating an interest in cognition in epilepsy, and in raising the relevance of cognitive side effects of drugs for quality of life (QoL) in epilepsy3.
The recent years have seen the introduction of several new anticonvulsants into clinical practice. Disappointingly, with the exception of vigabatrin4y5, there has been little attempt to assess the effects of these drugs on cognition. In this study we present the results of an add-on study with gabapentin, in which effects on cognition and QoL have been measured.
MATERIALS AND METHODS

Participants
Thirty outpatients with chronic epilepsy, attending the National Hospital for Neurology and Neurosurgery, London, took part in the study. Patients were invited to participate if they were 18 years of age or over, and were either to begin gabapentin as add-on therapy, or to remain on a stable drug regime. Patients were not assigned randomly to groups, but on clinical grounds. Patients with moderate to severe learning disability were not included in the study due to constraints imposed by task requirements. Patients who might be classified as having learning difficulties or a mild learning disability were included in the study, so representing patients who might experience difficulty with learning secondary to epilepsy-related variables (e.g. brain damage, seizure frequency, medication). Written informed consent was obtained from all participating patients. Blood was taken for assessment of gabapentin levels as soon as possible after cognitive testing was performed.
Cognitive measures
Critical Flicker Fusion (CFF)6
The Critical Flicker Fusion (CFF) task was developed to measure 'central integrative ability' and has been shown to be sensitive to both sedative and stimulant drug effects.
The CFF is presented using the Leeds Psychomotor Tester. The Tester contains four light-emitting diodes (LEDs) which flicker at either an increasing rate (the 'Up' condition) or a decreasing rate (the 'Down' condition). On each trial, participants are asked to focus on a set of four lights. In the 'Up' condition, the lights appear to be flickering at the start of each trial, and participants are asked to press a switch as soon as the lights appear to stop flickering. In the 'Down' condition, the lights appear to be still at the start of each trial, and participants are asked to press the same switch as soon as the lights appear to start flickering. Two 6-trial blocks are administered for each condition, and conditions alternate between blocks. The Leeds Psychomotor Tester records the flicker-detection threshold (cycles per second) for each trial. The mean flicker-detection threshold of all 24 trials (collapsed across the two conditions) is taken as the measure of performance.
Verbal Memory (VM; Evans. Thompson, personal communication) The Verbal Memory task measures recognition and recall (immediate and delayed) of newly learned verbal material, and is comparable to the Rey Auditory Verbal Learning test'. Separate stimulus sets are used at preand post-treatment assessment. This task was used in this study to yield four measures of verbal memory performance. For all four measures, false-negative but not false-positive errors were accounted for by the measure of performance.
Immediate recall. A list of 12 words was read aloud to participants at a rate of one word per second. Participants were then asked to recall as many words from the list as they could (in any order). The number of correctly recalled words (/12) on this first trial was taken as the measure of immediate recall.
Best recall. The above procedure was repeated until participants had either correctly recalled all 12 words, or the maximum of eight trials had been administered. The highest number of correctly recalled words (/12) achieved on any trial was taken as the measure of best recall.
Recognition. Participants were then given a list of 60 written words, arranged in three columns of 20 words each. The list included the 12 previously presented target words scattered among 48 new distractor words. Participants were asked to identify the previously presented target words. The number of correctly recognized words (/12) was taken as the measure of recognition.
Delayed recall. Approximately 1 hour following the immediate recall task, participants were asked to recall as many of the 12 target words as they could. The number of correctly recalled words (/12) was taken as the measure of delayed recall.
Paced Auditory Serial Addition Task (PASAT)
The Paced Auditory Serial Addition Task (PASAT) measures attention and concentration, working memory and mental flexibility, and also requires simple mental arithmetic and mental speed.
Four lists, each of 50 single-digit numbers, are presented aurally with a tape-recorder. The pace, or rate of presentation of numbers, increases with each successive list (one number every 2.4, 2.0, 1.6, and 1.2 seconds, respectively). For each list, participants are asked to add each number to the preceding number, and then to say the sum aloud, before the subsequent number is presented (e.g. '11, 10, 7.: in response to the numbers '3, 8, 2, 5..'). For this study, the first list (2.4 seconds) was used as a practice trial. The number of correct additions (/49) for each of the three remaining lists (2.0, 1.6 and 1.2 seconds) were taken as the measures of performance.
Stroop Neuropsychological Screening Test (SNST)g
The standard Stroop interference task is widely used as a measure of attention, but also measures prepotent inhibition and thus is an aspect of executive function. Trenerry and colleagues' version of the standard Stroop task (the Stroop Neuropsychological Screening Test; SNST) is recommended for use with adults from 18 years of age, with the usual conditions that participants must be fluent readers of English, and have no (uncorrected) visual impairment of acuity or colour vision. The SNST has two conditions. In each condition, participants are presented with a list of 112 stimulus items arranged in four columns each of 28 items. Each item is a colour-word printed in a conflicting coloured ink (e.g. the colour-word 'RED', printed in blue ink). In the first condition, participants are instructed to read aloud the colour-words (word-reading), and in the second condition, participants are instructed to name aloud Effects of gabapentin on cognition and quality of life 361 the ink-colour in which the words are printed (colournaming). In both conditions, participants are asked to respond as quickly and as accurately as they can. For each condition, the number of correct responses (/112) achieved within 2 minutes is taken as the measure of performance. Correct responses include errors which are spontaneously corrected, as the time taken to correct the error is necessarily accounted for by the dependent measures.
Quality of life (QoL) measures
General Health Questionnaire-30
The General Health Questionnaire (GHQ) is a selfrating questionnaire designed as a screening instrument for psychiatric case identification, with a focus on psychological components of ill-health. The GHQ measures breaks in normal function (i.e. inability to continue normal healthy functions, and the appearance of new distressing phenomena) rather than lifelong traits, and so is sensitive to transient disturbance. Although designed to discriminate between predicted cases and non-cases, the GHQ can also be used as a dimensional measure of psychological disturbance. The abbreviated GHQ-30 was selected among the various versions of the GHQ, as it is recommended for use with patients with physical illness. The Likert (O-l-2-3) scoring system was used to measure the degree of psychological disturbance, to maximize sensitivity to change. The dependent measure is a total score (/90), which reflects the degree of self-rated disturbance.
Epilepsy Surgery Inventory-55 (ESI-55)' '
The Epilepsy Surgery Inventory-55 (ESI-5.5) is a 55-item measure of health-related QoL, designed to assess the effects of surgery on patients with epilepsy. The ESI-55 can also be used to assess the effects of anticonvulsant medication on patients with epilepsy. Three composite scores (/lOO) can be calculated, higher scores indicating a higher QoL. These composite scores, mental health, physical health, and role functioning, were used as the dependent measures for this study.
Procedure
Patients were tested individually at the Institute of Neurology. For baseline assessment, patients were seen following an outpatient clinic appointment. All patients were scheduled to be seen again l-2 months later for post-treatment assessment. Following baseline assessment, patients in the gabapentin group were started on a dose of 400 mg gabapentin, increasing by 400 mg weekly over 4 weeks to reach a target dose of 1600 mg (i.e. weeks 14: 400,800,1200,1600 mg, respectively). For both pre-and post-treatment assessment, the cognitive battery was administered before the QoL measures. The cognitive tests were administered in the following order: VM (Immediate Recall, Best Recall, Recognition), CFF, SNST, PASAT, VM (Delayed Recall). The GHQ-30 followed by the ESI-55 were administered at the end of each testing session.
RESULTS
Patients in the gabapentin group were aged between 24:3 and 71:3 (years:months), with a mean of 39:9 (SD = 14: 5). The gabapentin group consisted of six males and nine females, giving a sex ratio of 1: 1.5 (male:female). Patients in the control group were aged between 21:8 and 61:6, with a mean age of 37:2 (SD = 11: 1). The control group consisted of eight males and seven females, giving a sex ratio of 1.1: 1 (male:female). No significant between-group differences were found for age or sex (Age: two-tailed independent samples r-test, t(28) = 0.56; Sex: two-tailed Pearson, chi-square; chi( 1) = 0.54; both p > 0.05).
Baseline clinical details for each patient group are shown in Tables 1 and 2 . For the gabapentin group, post-treatment gabapentin dosages ranged from 800-1600mg,withameanof 1428.6(SD = 302.4;n = 14). Blood serum levels for gabapentin were available for nine of the gabapentin patients. Among these patients, post-treatment serum levels ranged from 5 to 62, with a mean of 29.9 (SD = 19.1).
Cognitive measures
Mean pre-and post-treatment scores on cognitive measures for the gabapentin and control groups are shown in Table 3 .
Between-group two-tailed independent samples ftests were performed on difference scores (post-minus pre-treatment). A significant difference was found on the word-reading condition of the SNST (t(26) = 2.26, p <: 0.05), in favour of the gabapentin group. No significant differences were found for any of the remaining cognitive measures (CFF: r(28) = 0.80; VM Immediate Recall: t(28) = 0.39; VM Best Recall: t (28) = 0.45; VM Delayed Recall: t (28) = 0.74; VM Recognition: t (28) = 1.03; PASAT 2.0s: following Levene's test for homogeneity of variances, adjusted r( 19.0) = 0.65; PASAT 1.6s r(27) = 0.93; PASAT 1.2s t(27) = 0.71; SNST colour-naming t(26) = 0.27; all p > 0.05). Between-group comparisons are shown in Table 3 .
Within-group two-tailed paired samples f-tests were also performed to test for differences on cognitive measures between pre-and post-treatment, for each group respectively. For the gabapentin group, significant improvement was found on all PASAT measures and both SNST measures (PASAT 2.0s: t (14) = 2.50; PASAT 1.6s t(14) = 2.32; PASAT 1.2s: t(14) = 2.48; SNST word-reading t(13) = 2.28; SNST colour-naming t (13) = 2.48; all p .c 0.05). For the control group, significant improvement was found on the least demanding PASAT measure only (PASAT 2.0s: f (13) = 4.15, p < 0.05). Within-group comparisons are shown in Table 3 .
For the gabapentin group, two-tailed Spearman's correlations were performed between gabapentin serum levels and cognitive difference scores. Gabapentin serum level was significantly positively correlated with VM Delayed Recall (r(9) = 0.70, p = 0.036), but not with any of the remaining cognitive measures.
Quality of life (QoL) measures
Mean pre-and post-treatment scores on the GHQ-30 and the ESI-55 for the gabapentin and control groups are shown in Table 4 .
Between-group two-tailed independent samples ttests were performed on difference scores (post-minus pre-treatment). No significant difference was found on the GHQ30 (t(28) = 0.52, p > 0.05) or on any of the ESI-55 composite score (Mental Health: t(28) = 0.16; Physical Health: t(28) = 0.45; Role Functioning: r(28) = 0.43; all p > 0.05). Betweengroup comparisons are shown in Table 4 .
Within-group two-tailed paired samples r-tests were performed to test for differences on QoL measures between pre-and post-treatment, for each group respectively. For the gabapentin group, significant improvement was found on all ESI-55 composite scores (Mental Health: t (14) = 2.26; Physical Health: r (14) = 2.39; Role Functioning: t(14) = 2.36; all p < 0.05). For the control, significant improvement was found on two ESI-55 composite scores (Mental Health: t (14) = 2.92; Role Functioning: t (14) = 2.23; both p -c 0.05). Within-group comparisons are shown in Table 4 .
For the gabapentin group, two-tailed Spearman's correlations were performed between gabapentin serum levels and QoL difference scores. No significant correlations were found between gabapentin serum level and any of the QoL measures.
Seizure frequency
No significant between-group difference was found for baseline seizure frequency (two-tailed indepen- dent samples r-test, f (25) = 1.21, p > 0.05), or for seizure frequency difference scores (post-minus pre-treatment; two-tailed independent samples r-test, t(25) = 0.25,~ > 0.05).
DISCUSSION
In this study we have assessed the effects of adding on gabapentin to the existing therapy of patients with intractable epilepsy, receiving the drug in a clinical setting. Ideally, we would have conducted a placebocontrolled study, with monotherapy, but ethical constraints do not allow such a design. We have therefore followed a design we have used previously, especially testing a matched control group, that do not undergo any changes of therapy with the same protocol. This allows a control for the experimental setting, and for practice effects. The cognitive tests we used were similar to those we have used previously5, namely tests with minimal motor components, as it has been suggested that much of Effects of gabapentin on cognition and quality of life 363 the effect of these drugs on cognitive function relates to motor slowing. We have always been more interested in effects on higher cognitive, as opposed to psychomotor, function. In this study we also included assessment of QoL. Measuring QoL is still in its relative infancy compared with cognition, and there are few studies on the effects of anticonvulsants on such measures. We chose the ESI-55 as it has been used in several recent studies' ', and has been shown to have reliable clinimettics, including responsiveness, to surgical intervention at least. As psychopathology, especially depression, is an important component of QoL, we also included the GHQ.
The most import@ conclusion from the data reflects on the lack of an observable negative influence on either cognition or QoL from the addition of gabapentin. There are significant improvements in both groups in cognitive function, and the profile (Table 3) implies more widespread improvements in the gabapentin group, compared with the comparison group. While we would not overemphasize the significance of this from this study, with its design, these data add to and substantiate other cognitive studies with gabapentin.
Leach et a112, using a double-blind design, gave a battery of psychomotor and memory tests to patients, and examined the effect of different doses. They found no effects of the active drug.
Arnett et alI3 used a cognitive battery of 19 variables and a QoL questionnaire to assess the effects of gabapentin in a large double-blind study of intractable patients, and included a group (n = 106) on monotherapy with the drug. Patients on polytherapy or monotherapy showed significant improvements, notably with faster perceptual and motor performance on the drug.
Finally, although again with small numbers, we did note a significant correlation between one of our cognitive measures and a change of serum level of gabapentin. While this may have been a chance result from a type-2 error, such pharrnacodynamicpharmacokinetic relationships may be relevant to the interpretation of the overall results.
With regards to measures of QoL, Leach et alI2 gave the SEALS, a questionnaire designed essentially to detect drug side effects, rather than QoLperse. No effects were noted over the 12 weeks of the study. In the study of Amett etal13, improvements on the Washington Psychosocial Inventory (WPSI) were reported, especially for the subscales of personal and interpersonal adjustment. Dimond et al'" also assessed the possible influence of gabapentin on mood and general well-being in 194 patients from an overall 423 patients taken from five double-blind trials with the drug. Global assessments and Activities of Daily Living were evaluated, but not in a good systematic way. There were suggestions that patients reported improved QoL, irrespec-tive of control of seizures, and especially at higher doses (1800 mg). These data hinted that gabapentin may have, like some other anticonvulsants'5, an independent effect on mood. Recent anecdotal reports of its effect as a mood stabilizer in bipolar affective disorder supports this suggestion16, but further studies are needed. Our own data are inconclusive, the only difference between the groups being on physical health, significant only in the gabapentin group. This was not associated with control of seizures (correlations between change of seizures and this variable not being significant). However, the timescale of our study was too short to make many comments regarding the influence of gabapentin on QoL. We will complement these data soon with longer term QoL follow-up data. From this study we emphasize only the lack of any adverse influence.
It is interesting to note the improvements in QoL scores in the comparison group. This either reflects on the clinimetric properties of the ESI-55, suggesting lack of reliability over time, or the influence of simply taking patients such as these into a study and carrying out cognitive and QoL tasks. We are inclined to suspect the latter, which in part explains the well-observed placebo effect of anticonvulsants in placebo-controlled clinical trials.
We conclude that the addition of gabapentin to intractable patients with epilepsy as polytherapy in the dose range we have given has no detectable adverse influences on cognitive function or QoL, and the data suggest, if anything, some positive influences. While we cannot conclude the latter definitively from our design, these data are in keeping with the few other studies with this drug that have been reported. Clearly, further work on the influence of gabapentin on mood and QoL would be of value.
